CalciMedica and Telperian have joined forces to incorporate an AI engine into trial datasets analysis from completed Auxora studies.
The partnership will concentrate on AI-driven analysis of Auxora, a calcium release-activated calcium channel inhibitor designed for the treatment of immunological disorders and acute inflammation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This clinical compound of CalciMedica has undergone assessment in several efficacy studies, notably the Phase IIb CARPO trial involving participants with systemic inflammatory response syndrome (SIRS), acute pancreatitis (AP) as well as the Phase II CARDEA trial focusing on individuals with severe Covid-19 pneumonia.
CalciMedica is presently engaged in discussions with the US Food and Drug Administration (FDA) regarding the design of a pivotal trial for Auxora in the context of AP.
Auxora is currently undergoing evaluation in the Phase II KOURAGE trial involving subjects with acute kidney injury accompanied by respiratory failure, with results anticipated in early 2026.
The collaboration will analyse datasets from completed clinical trials and perform simulations based on data from third-party trial publications.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTelperian’s platform integrates domain expertise, biostatistics and AI to deliver insights into treatment benefits across identifiable patterns and patient subtypes.
Furthermore, it will conduct emulations of historical studies in critical care to extract insights for the planning of a pivotal programme for the compound.
CalciMedica CEO Rachel Leheny said: “CARPO and CARDEA are two critical trials contributing to the strong body of evidence supporting Auxora as a potentially transformative treatment for acute inflammatory and immunologic illnesses.
“Telperian’s advanced AI engine will be beneficial in the further analysis of these trials, allowing us to dig deeper into the effects of Auxora, to refine our identification and understanding of treatment effects across patient subgroups, and to enhance the design of our pivotal programme in AP. We are eager to review the findings and share them with the FDA as we discuss pivotal development of Auxora.”
